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Effect of Valsartan on Angiotensin II–Induced Plasminogen
Activator Inhibitor-1 Biosynthesis in Arterial Smooth
Muscle Cells
Luigi Sironi, Anna Maria Calvio, Lorenzo Arnaboldi, Alberto Corsini, Alessandro Parolari,
Marc de Gasparo, Elena Tremoli, Luciana Mussoni
Abstract—Previous studies have shown that angiotensin II stimulates the synthesis of plasminogen activator inhibitor-1 in
cultured vascular cells, which suggests that activation of the renin-angiotensin system may impair fibrinolysis. We have
investigated the effects of angiotensin II and of valsartan, a recently developed angiotensin II antagonist that is highly
specific and selective for the angiotensin II subtype 1 receptor, on plasminogen activator inhibitor-1 secretion by smooth
muscle cells isolated from rat and human vessels. Angiotensin II induced a time- and concentration-dependent increase
of plasminogen activator inhibitor activity in supernatants of rat aortic cells, which reached a plateau after 6 hours of
incubation with 100 nmol/L angiotensin II (2.460.6-fold over control value; P,0.001). The angiotensin II–induced
plasminogen activator inhibitor activity was inhibited, in a concentration-dependent manner, by valsartan with an IC50
value of 21 nmol/L. Valsartan fully prevented the angiotensin II–induced increase in plasminogen activator inhibitor-1
protein and mRNA. Furthermore, angiotensin II doubled the secretion of plasminogen activator inhibitor-1 by smooth
muscle cells obtained from human umbilical and internal mammary arteries, and valsartan fully prevented it.
Angiotensin II did not affect the secretion of tissue plasminogen activator antigen by any of the cell systems tested. Thus,
valsartan effectively inhibits angiotensin II–induced plasminogen activator inhibitor-1 secretion without affecting that
of tissue plasminogen activator in arterial rat and human smooth muscle cells. (Hypertension. 2001;37:961-966.)
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Activation of the renin-angiotensin system (RAS) isassociated with an increased risk of ischemic cardiovas-
cular events independently of its effects on blood pressure.1
Conversely, the inactivation of RAS, with angiotensin-
converting enzyme (ACE) inhibitors, reduces the risk of
recurrent myocardial infarction in patients with left ventric-
ular dysfunction,2 reduces intimal thickening after vascular
injury,3 and in experimental models decreases progression of
atherosclerosis.4
Angiotensin II (Ang II) is responsible for the RAS-
mediated cardiovascular complications,5 and therefore the
beneficial effects of ACE inhibitors derive mainly from their
reduction of the biosynthesis of this autacoid. A non–ACE-
dependent Ang II formation resulting from the action of a
chymase enzyme occurs in the heart and in normal and to a
greater extent in atherosclerotic vessel walls.6,7 This may
limit the effectiveness of ACE inhibitors.
Ang II receptor antagonists, and in particular antagonists of
the Ang II subtype 1 (AT1) receptor, form a recently devel-
oped class of drugs that suppress both the ACE- and non–
ACE-dependent vascular effects of Ang II and that are
therefore better at preventing cardiovascular effects than
simple ACE inhibitors.8
Plasminogen activator inhibitor-1 (PAI-1) is a key regula-
tor of fibrinolysis, and accumulating data suggest that ele-
vated PAI-1 levels in plasma are a risk factor for arterial
thrombotic disease.9 The interaction of Ang II with the
fibrinolytic system has recently gained attention.10 Infusion of
Ang II, in both normotensive and hypertensive subjects,
increases the circulating levels of PAI-1.11 Moreover, Ang II
increases the levels of PAI-1 antigen and mRNA in cultured
bovine and rat aortic endothelial cells as well as the level of
PAI-1 mRNA in human umbilical vein endothelial cells.12,13
In addition, Ang II has been shown to increase PAI-1
expression in smooth muscle cells (SMCs) isolated from rat
aorta, through an interaction with the AT1 receptor sub-
type.13,14 No information is available, however, on the effect
of Ang II on PAI-1 biosynthesis by human SMCs.
SMCs represent the most abundant cell type in the vessel
wall, and their contribution to the local and systemic fibrino-
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lytic balance is of particular relevance. Increased PAI-1
expression was noted in the thickened intima at the base of
human atherosclerotic plaques.15 This may result in an
impairment of the plasmin-mediated proteolytic cascade,
which controls extracellular matrix degradation and vessel
wall function. Interestingly, inhibition of ACE has been
shown to reduce PAI-1 expression in the neointima of rat
balloon-injured aortas.16 In this condition, enhancement of
luminal fibrinolysis and extracellular matrix turnover may
occur. Indeed, plasmin generation is part of the proteolytic
machinery regulating the activation of matrix metalloprotein-
ases within the vessel wall.17 Interestingly, Ang II–forming
activity has been found in atherosclerotic as well as in
aneurysmal lesions.6
In view of the relevance of the effects of Ang II on the
fibrinolytic potential of vascular SMCs, we investigated the
effects of valsartan,18 a highly specific and selective antago-
nist of the AT1 receptor, on the formation of PAI-1 and tissue
plasminogen activator (tPA) by rat aortic SMCs isolated from
normal and hypertensive rats. We have extended the study to
human SMCs isolated from various arterial locations.
Methods
Cell Culture and Experimental Procedures
Rat aortic SMCs were obtained according to Ross,19 from intima-
media layers of aorta of Sprague-Dawley rats, Wistar-Kyoto rats
(WKY), or spontaneously hypertensive rats (SHR). Procedures
involving animals and their care were conducted in conformity with
the National Institutes of Health Guide for the Care and Use of
Laboratory Animals. Cells were grown as previously described and
used at passages 3 to 9.20 Human SMCs were isolated from pieces of
internal mammary arteries obtained from patients undergoing car-
diopulmonary bypass surgery and from arteries of human umbilical
cords obtained at normal deliveries. This was approved by the
Institutional Referee Board of the Cardiology Center Walter
Monzino (Milan, Italy). Human SMCs were cultured in M199
supplemented with 20% FCS and used at passages 2 to 8. Cells were
confirmed to be SMCs by morphology and positive staining to
a-actin.21
Experimental Procedures
Rat aortic SMCs (2.53105) were seeded in 35-mm dishes and
cultured to subconfluence in complete medium (modified Eagle’s
medium). Human SMCs (33104) were seeded in 24-well plates and
cultured to confluence in complete medium 199. Cells were incu-
bated for different times in serum-free medium with the appropriate
substances after 24 hours in serum-free medium for rat cells and 48
hours in 0.4% FCS medium for human cells. At the end of the
incubation, the conditioned medium (CM) was collected and stored
in aliquots at 220°C until analyzed. Cells were dissolved with 0.2
mol/L NaOH to determine cellular protein. Valsartan, kindly pro-
vided by Novartis Pharma (Basel, Switzerland), was dissolved in
KOH (0.1 mol/L), adjusted to pH 8 with HCl, and diluted in sterile
PBS at 1 mmol/L concentration. Equivalent volume of the solvents
was added in control cells. Captopril, PD123319, saralasin, and Ang
II (Sigma Chemical Co) were dissolved in sterile PBS at 1 mmol/L
concentration. Unless otherwise stated, drugs were incubated with
cells for 10 minutes before the addition of Ang II.
Determination of Plasminogen Activator
and PAI-1
PAI was measured by an indirect chromogenic assay (pPAR/L,
Biopool, DK). Briefly, different amounts (5 to 20 mL) of CM were
incubated in 96-well plates for exactly 10 minutes at room temper-
ature with a fixed concentration of tPA standard (1 IU/mL). After 1
to 2 hours of incubation at 37°C, plasmin generation was assessed at
405 nm in a spectrophotometric plate reader. PAI activity is
expressed as arbitrary units (AU/mL) using reference curves of
standard tPA. Plasminogen activator (PA) activity of the conditioned
medium was evaluated in the same assay described for PAI activity
except that tPA was omitted from the reaction mixture. Data are
expressed as PA activity using reference curves of standard tPA.
Determination of PAI-1 and tPA Antigen
PAI-1 and tPA were measured in medium collected from human
SMCs by specific ELISAs (Imulyse, Biopool). Data are expressed as
nanograms PAI-1 or tPA antigen per microgram cell protein.
Immunoblotting for PAI-1
CM (1 mL) of cells incubated for 6 hours with vehicle or Ang II in
the presence or absence of valsartan was precipitated, separated by
SDS-PAGE, and transferred to nitrocellulose as described.13 PAI-1
protein was recognized with a specific monoclonal antibody (MA-
33H1), a kind gift of Professor P.J. Declerck, Katholieke Universiteit
Leuven,22 and revealed with anti-mouse IgG (Amersham Pharmacia
Biotech), conjugated with peroxidase. Positive bands were visualized
after exposure to Hyperfilm ECL (Amersham).
Measurements of Rat PAI-1 mRNA by Reverse
Transcriptase–Polymerase Chain Reaction
Total RNA from rat cells was prepared with the use of TRIzol (Gibco
Life Technologies) in accordance with the manufacturer’s instruc-
tions. The levels of rat PAI-1 and GAPDH mRNA in the differently
treated samples were detected using a reverse transcriptase–poly-
merase chain reaction (RT-PCR) performed as previously
described.23
Statistical Analysis
Data are expressed as mean6SEM. Statistical analysis was per-
formed with ANOVA followed by Tukey’s test. Differences were
taken as statistically significant at P,0.05.
Results
Ang II–Induced PAI-1 in Human and Rat
Arterial SMCs
Initial studies were performed to assess the effects of Ang II
on PAI activity of rat aortic SMCs. PAI activity in CM of
unstimulated rat SMCs was measurable at 2 hours (1.460.39
AU/mL; n56) and did not change up to 16 hours (1.760.3
AU/mL; n53). Ang II incubated with rat SMCs for 6 hours
concentration-dependently increased PAI activity, reaching
the maximum effect at 100 nmol/L (2.460.3 times the control
value; n59; P,0.01) (Figure 1B). The effect of Ang II was
time dependent, starting at 2 hours, reaching a plateau after 6
hours, and remaining constant up to 16 hours (Figure 1A).
The PA activity of rat SMCs, by contrast, was very low,
being barely detectable in both unstimulated and Ang II–
stimulated rat SMCs.
To determine whether the increase in PAI activity exerted
by Ang II was due to increased amounts of PAI-1 released
from cells, we detected PAI-1 antigen by Western blotting of
CM collected from rat SMCs unstimulated or incubated 6
hours with Ang II (100 nmol/L) (Figure 1C). The Ang
II–induced PAI-1 antigen increases in CM from rat SMCs
paralleled the increase of PAI-1 mRNA steady state levels as
assessed by RT-PCR (Figure 1D). The capacity of Ang II to
modulate the synthesis of PAI-1 in human SMCs obtained
from 2 arterial locations (internal mammary and umbilical
arteries) was then evaluated. To this end, human SMCs were
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incubated for 6 hours in serum-free medium with or without
Ang II (100 nmol/L). Ang II doubled PAI-1 antigen secretion
by the umbilical artery SMCs (P,0.01) and, to a lesser
extent, by SMCs isolated from internal mammary artery
(P,0.05) (Figure 2).
tPA antigen levels in unstimulated SMCs obtained from
human arteries were only weakly detectable and did not
change after exposure to 100 nmol/L of Ang II (data not
shown).
Modulation of PAI Ang II Induced in Rat and
Human SMCs by Valsartan
The involvement of Ang II receptor subtypes in the stimula-
tory effect of Ang II on PAI-1 secretion was then investi-
gated. In rat aortic SMCs, [Sar1-Ile8]Ang II (saralasin), a
nonspecific Ang II receptor subtype antagonist, and
PD123319, a selective antagonist of the AT2 receptors, did
not affect basal levels of PAI activity up to 1 mmol/L
concentration. In cells exposed for 6 hours to 100 nmol/L
Ang II instead, saralasin completely prevented the increase in
PAI activity induced by Ang II, whereas PD123319 (100 to
1000 nmol/L) had no effect (data not shown). The role of the
AT1 receptor subtype was therefore examined by incubating
rat SMCs with valsartan. Valsartan (0.01 to 1000 nmol/L)
prevented the increase of PAI activity induced by Ang II in a
concentration-dependent manner, with an IC50 of 21 nmol/L
(Figure 3A). In the presence of 100 nmol/L valsartan, a
parallel rightward shift of the concentration-response curve of
Ang II–induced PAI activity was recorded (EC50 from 1.7 to
75 nmol/L with Ang II alone and in the presence of valsartan,
respectively), with no change in the maximal effect of Ang II
(Figure 3B). The R-enantiomer of valsartan failed to affect
PAI activity induced by Ang II (data not shown), indicating
that the effect of the drug is stereospecific.
Prior treatment (14 to 16 hours) of rat SMCs with captopril
(1 mmol/L), which prevents the conversion of angiotensin I to
Ang II, did not influence the effects of either Ang II or
valsartan on PAI activity. This observation rules out the
possibility of an effect of endogenous Ang II in our experi-
mental system. Valsartan at 100 nmol/L prevented the effect
of Ang II (100 nmol/L) on the levels of rat PAI-1 antigen as
well as on PAI-1 mRNA (Figure 4A and 4B). Moreover,
valsartan completely prevented the effect of Ang II on PAI-1
secretion by human SMCs from either internal mammary or
umbilical arteries (Figure 5).
The effect of valsartan on the Ang II–induced PAI activity
was also investigated in SMCs isolated from the aorta of
SHR. Ang II (100 nmol/L) increased PAI activity of SHR
SMCs by 3.360.2-fold, and this effect was significantly
greater than that exerted by Ang II on SMCs isolated from
aorta of WKY (2.0660.1-fold; n53; P,0.01 versus SHR
SMCs), which is the related control strain. Valsartan (100
nmol/L) completely prevented the increase in PAI activity
induced by Ang II in SMCs isolated from aorta of both rat
strains (data not shown).
Discussion
In this study we show that Ang II impairs the fibrinolytic
potential of human and rat arterial SMCs by increasing the
Figure 1. Effects of Ang II on PAI activity, protein accumulation,
and mRNA synthesis by rat aortic SMCs. The cells were incu-
bated with 100 nmol/L of Ang II for the indicated time (A) or for
6 hours with different concentrations of Ang II (B). C and D, Rat
aortic SMCs were incubated for 6 hours in medium with or with-
out Ang II 100 nmol/L. CM was then precipitated, separated by
SDS-PAGE, and immunoblotted with a monoclonal antibody
against rat PAI-1 (C). Total RNA was extracted, and PAI-1 and
GAPDH mRNA levels were estimated by RT-PCR (D). A and B,
Each bar represents the mean6SEM of at least 6 independent
experiments performed in duplicate (**P,0.01 vs vehicle-treated
rats). C and D, One typical experiment of 4 is represented.
Figure 2. Ang II–induced PAI-1 release into the supernatants of
human SMCs isolated from umbilical (p) and internal mammary
(N) arteries. Cells were incubated for 6 hours with or without Ang
II (100 nmol/L). PAI-1 antigen levels were determined in CM with
specific ELISAs. Each bar represents the mean6SEM of 3 inde-
pendent experiments performed in duplicate (**P,0.01, *P,0.05
vs the corresponding control).
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synthesis of PAI-1 and that this effect is reversed by valsar-
tan, a highly specific AT1 receptor antagonist.
In situ hybridization and immunohistochemical studies
have demonstrated the presence of PAI-1 on the vascular
wall, with a significant increase in its concentration during
the progression from normal vessel to fatty streaks and to
atherosclerotic plaques.15 Recent studies have shown an
increase of local PAI-1 mRNA expression, predominantly in
SMCs, within human atherosclerotic lesions.24
PAI-1 production by SMCs is increased by platelet-
associated growth factors and Ang II.13,25 In particular, Ang II
exerts hypertrophic and proliferative growth actions for
SMCs.26 These observations suggest a relationship between
PAI-1 expression and cell proliferation and support the
concept that high expression of PAI-1 may correlate with the
progression of atherosclerosis.
PA, whether measured as tPA antigen in the CM of human
SMCs or as PA activity in rat SMCs, was barely detectable,
and these levels did not change after stimulation of cells with
Ang II. Thus, Ang II reduces the fibrinolytic potential of
SMC as the result of a specific increase in PAI-1
biosynthesis.
The positive effect of Ang II on PAI-1 biosynthesis in
cultured rat aortic SMC is mediated by an interaction of this
autacoid with the AT1 receptor.13,14 Our data indicate that
Ang II increases PAI-1 biosynthesis in human arterial SMCs
by a similar mechanism. Valsartan, a highly specific AT1
receptor antagonist, completely prevented the enhancing
effects of Ang II on PAI-1 secreted by human arterial SMCs.
ACE inhibitors have been widely used to block RAS and to
treat hypertension and congestive heart failure; however,
despite their recognized clinical efficacy, they have some
Figure 3. Effects of valsartan on the PAI activity induced by Ang
II in rat aortic SMCs. A, Cells were incubated for 10 minutes
with different concentrations of valsartan (1 to 500 nmol/L)
before the addition of 100 nmol/L Ang II for an additional 6
hours. CM of cells was then collected, and PAI activity was
measured. Values are the mean6SEM of 9 individual experi-
ments (**P,0.01 vs control). B, Cells were incubated for 10 min-
utes with a fixed concentration of valsartan (100 nmol/L) and
then challenged for an additional 6 hours with different concen-
trations of Ang II (1 to 1000 nmol/L). The curves obtained with
Ang II alone (l ) or in the presence of valsartan (n) represent the
mean6SEM of 4 individual experiments performed in duplicate.
Results are expressed as percentages of the maximum
response obtained with Ang II alone.
Figure 4. Effect of valsartan on PAI-1 protein accumulation and
mRNA synthesis in rat SMCs. Rat SMCs were incubated for 6
hours with vehicle (1) and in the presence of Ang II 100 nmol/L
(2), Ang II 100 nmol/L plus valsartan 100 nmol/L (3), or valsartan
alone (4), then CM was precipitated, separated by SDS-PAGE,
and immunoblotted with a monoclonal antibody against rat
PAI-1 (A). Total RNA was extracted from the treated cells, and
PAI-1 and GAPDH mRNA levels were estimated by RT-PCR (B).
A and B are representative of 3 experiments with similar results.
Figure 5. Effect of valsartan on Ang II–induced PAI-1 release
into the medium of human SMCs from umbilical (p) and internal
mammary (N) arteries. The cells were incubated for 6 hours with
or without Ang II (100 nmol/L), in the presence or absence of
valsartan (100 nmol/L). PAI-1 antigen levels were determined in
CM with specific ELISAs. Each bar represents the mean6SEM
of 3 independent experiments performed in duplicate (**P,0.01,
*P,0.05 vs corresponding control).
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weaknesses. ACE inhibition results in bradykinin accumula-
tion, which is a source of side effects such as cough and
angioedema. In addition, during ACE inhibition, plasma Ang
II levels decrease, but some Ang II is still measurable within
the circulation because of non-ACE biosynthesis of this
autacoid.27 Since most known effects of Ang II are mediated
by the AT1 receptor, AT1 receptor antagonists might be useful
as a local antagonist of the effects of Ang II that are also
derived from non-ACE pathways.28 Previous reports have
suggested that valsartan, a highly selective antagonist of the
AT1 receptor, is useful in lowering cardiovascular risk.18,29,30
This drug, beyond its blood pressure–lowering activity, im-
proves heart failure in rats with myocardial infarction, re-
duces endothelial dysfunction and intimal thickening in
atherosclerotic rabbits, and induces a significant regression of
left ventricular hypertrophy in patients with essential hyper-
tension.18,31–33 The effects of AT1 antagonists on fibrinolytic
balance, and in particular on PAI-1 and tPA plasma levels, in
normal subjects as well as in patients with cardiovascular
disease, are still controversial.34 Moreover, no clinical data on
valsartan, which possesses greater specificity and selectivity
for the AT1 receptor than losartan,35 are yet available. This
study shows that valsartan, at clinically relevant concentra-
tions,18 is effective in preventing Ang II–mediated PAI-1
biosynthesis in rat aortic SMCs isolated from normotensive
or hypertensive animals. This is consistent with the observa-
tion that valsartan was effective in preventing PAI-1 overex-
pression in kidneys of a rat model of high human renin
hypertension.36 Moreover, valsartan prevented the reduction
in fibrinolysis of hypercholesterolemic rabbits (M. de Gasp-
aro, personal communication).
Ang II receptor antagonists not only may control plasma
fibrinolytic potential but may also influence vessel wall
proteolytic properties, with a most prominent role within the
atherosclerotic plaque and or at the level of the migrating
and/or proliferating SMCs. This effect may be important in
preventing reduced plasmin generation that is due to the Ang
II–mediated increase in PAI-1 biosynthesis. As previously
mentioned, Ang II can be generated through a specific
chymase, and this is not affected by ACE inhibition.6 In
conclusion, we show that Ang II modulates the release of
PAI-1 from SMCs isolated from rat and human arteries and
that this effect is mediated by the interaction of Ang II with
AT1 receptors. Ang II may influence the synthesis of fibrino-
lytic factors in the medial layer of arterial vessels, thus
inhibiting the natural lysis of arterial thrombi and promoting
atherogenesis; these effects of Ang II are antagonized by
valsartan. We speculate that in vivo, AT1 receptor antagonists
represent a potential way to locally block the PAI-1 biosyn-
thesis induced by the Ang II that is generated not only by
ACE but also via non-ACE pathways.
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